Table 2.

Epigenetic Drugs Approved or under Clinical Trials

Category	Target	Approved drug and indications	Drugs under clinical trials
DNMT inhibitor	DNA methylation writers	Azacitidine (myelodysplastic syndromes), decitabine (myelodysplastic syndromes), procainamide (cardiac arrhythmias), hydralazine (essential hypertension), procaine (local anesthetics)	Tioguanine, FdCyd, TdCyd, Aza-TdCyd, fluorocyclopentenylcytosine, guadecitabine
HDAC inhibitor	Histone acetylation erasers	Vorinostat (cutaneous T cell lymphoma), romidepsin (cutaneous T cell lymphoma), belinostat (peripheral T cell lymphoma), panobinostat (multiple myeloma), valproic acid (seizures), chidamide (peripheral T-cell lymphoma, by CFDA)	Tacedinaline, mocetinostat, abexinostat, entinostat, pracinostat, resminostat, givinostat, quisinostat, kevetrin, tefinostat, nanatinostat, domatinostat, ricolinostat, ME-344, CG200745, CUDC-101, AR42
KMT6A inhibitor	Histone methylation writer	Tazemetostat (epithelioid sarcoma)	SHR2554, CPI-1205, GSK2816126, PF-06821497, MAK683
SIRT activator	Histone acetylation erasers	None	SRT2104
BET inhibitor	Histone acetylation readers	None	Mivebresib, molibresib, birabresib, INCB057643, ZEN003694, FT-1101, GSK2820151, CC-90010, CPI-0610, PLX51107, ABBV-744, BAY1238097, BI 894999, BMS-986158, GS-5829
PRMT5 inhibitor	Histone methylation writer	None	JNJ-64619178, PF-06939999, GSK3326595
PRMT1 inhibitor	Histone methylation writer	None	GSK3368715
KDM1A inhibitor	Histone methylation eraser	None	Seclidemstat, IMG-7289, tranylcypromine, GSK2879552, INCB059872, phenelzine sulfate
KMT4 inhibitor	Histone methylation writer	None	Pinometostat